Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-C137 |
| Synonyms | |
| Therapy Description |
BG-C137 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FGFR2b linked to a topoisomerase I inhibitor, which may induce cell cycle arrest and apoptosis in FGFR2b-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-C137 | BGC137|BG C137 | FGFR2 Antibody 5 | BG-C137 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FGFR2b linked to a topoisomerase I inhibitor, which may induce cell cycle arrest and apoptosis in FGFR2b-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06625593 | Phase I | BG-C137 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 2 |